Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating,
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …

CAR T cells are widely applied for relapsed hematological cancer patients. With six
approved cell therapies, for Multiple Myeloma and other B-cell malignancies, new insights …

Chimeric antigen receptor (CAR) T‐cell therapy is an immunotherapy approach that has
played a tremendous role in the battle against cancer for years. Since the CAR T …

Several studies have shown promise in many preclinical models of disease, including
simian immunodeficiency virus (SIV)/SHIV infection in nonhuman primates and HIV infection …

Chimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in
hematological malignancies and show great promise as treatment and curative strategy for …

Adoptive cell therapy (ACT) using T cells expressing chimeric antigen receptors (CARs) is
an area of intense investigation in the treatment of malignancies and chronic viral infections …

Current Opinion in HIV and AIDS Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with
bispecific chimeric antigen receptor T cells - PMC Skip to main content Here's how you know …

Simple Summary Knocking down genes by shRNAs in CAR T cells offers the potential of
expanding the therapy's efficacy beyond its initial success. Since shRNAs are in the CAR …

Infectious diseases remain a major burden on global public health and socio‐economic
stability. Despite that great progress has been made in the development of drugs, the …